GHK-Cu is a natural peptide in human blood plasma, urine, and saliva. Research in animals reveals that GHK-Cu can improve wound healing, immune function, and skin health by stimulating collagen, fibroblasts and promoting blood vessel growth. There has been evidence that has shown that it acts as a feedback signal that is generated after tissue injury. It also suppresses free-radical damage and thus is a potent antioxidant.
Overview
GHK-Cu is a naturally occurring peptide first isolated from human blood plasma. It has since been identified in urine and saliva as well. Research into GHK-Cu has found the short peptide to have substantial benefits in wound healing and immune function. It has anti-aging properties and has been found to suppress free-radical damage, increase protein synthesis, fight bacteria, and increase the health of skin and skin fibroblasts.
Scientific Journal Author
Loren Pickart, Ph.D. has released 109 publications and is developing patents and analyzing GHK’s effects on human gene expression of 4,192 genes. In addition to GHK’s published potential uses on skin inflammation, metastatic cancer and COPD, it appears to have beneficial effects on other tissue systems such as the nervous system, gastrointestinal system, and mitochondrial system. His brief but detailed autobiography dives into the motivations and background behind his dedicating to skin, anti-aging, and life-long training.
Loren Pickart, Ph.D is being referenced as one of the leading scientists involved in the research and development of GHK-Cu. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Loren Pickart, Ph.D is listed in [1] [3] and [8] under the referenced citations.
Reviews
There are no reviews yet.